2026-05-22T00:02:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/226602024-11-28T18:47:11Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16963col_20.500.12105_16967col_20.500.12105_16969col_20.500.12105_16982

00925njm 22002777a 4500 dc Puente, Javier author Gonzalez-del-Alba, Aranzazu author Sala-Gonzalez, Nuria author Jose Mendez-Vidal, Maria author Pinto, Alvaro author Rodriguez, Angel author Cuevas Sanz, Jose Miguel author Rodrigo Munoz del Toro, Jacobo author Rodriguez, Eduardo Useros author Garcia Garcia-Porrero, Angela author Vazquez, Sergio author 2019-08-05 Background: To describe the patterns of second-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel treatment in a Spanish population, to identify the factors associated with those patterns, and to compare the efficacy and safety of the treatments most frequently administered. Methods: Observational, prospective study conducted in patients with histologically or cytologically confirmed prostate adenocarcinoma; documented metastatic castration-resistant disease; progression after first-line, docetaxel-based chemotherapy with or without other agents. Results: Of the 150 patients recruited into the study, 100 patients were prescribed abiraterone acetate plus prednisone (AAP), 44 patients received cabazitaxel plus prednisone (CP), and 6 patients received other treatments. Age (odds ratio [OR] 1.06, 95% [confidence interval] CI 1.01 to 1.11) and not elevated lactate dehydrogenase (LDH) levels (OR 0.33, 95% CI 0.14 to 0.76) were independently associated with the administration of AAP. Treatment with AAP was associated with significantly longer clinical/radiographic progression-free survival (hazard ratio [HR] 0.57, 95% CI 0.38 to 0.85) and overall survival (OS; HR 0.40, 95% CI 0.21 to 0.76) compared to CP, while no significant differences between the treatments were found regarding biochemical progression-free survival (PFS; HR 0.78 [95% CI 0.49 to 1.24]). However, in a post-hoc Cox regression analysis adjusted for potential confounders there were not differences between AAP and CP in any of the time-to-event outcomes, including overall survival. We observed no new safety signals related to either regimen. Conclusion: Second-line AAP for patients with mCRPC is the most common treatment strategy after progression with a docetaxel-based regimen. When controlling for potential confounders, patients receiving this treatment showed no differences in PFS and OS in comparison to those receiving CP, although these latter results should be confirmed in randomized controlled trials. Puente J, Gonzalez Del Alba A, Sala-Gonzalez N, Mendez-Vidal MJ, Pinto A, Rodriguez A, et al. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC Cancer. 2019 Aug 05;19(1):766. 10.1186/s12885-019-5974-9 1471-2407 BMC Cancer http://hdl.handle.net/20.500.13003/15464 31382926 L628792407 2-s2.0-85070396213 https://hdl.handle.net/20.500.12105/22660 479241800008 Metastatic castration-resistant prostate cancer Abiraterone acetate Cabazitaxel Chemotherapy Sequence Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO)